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Cerebral venous thrombosis (CVT) is a relatively rare condition that results from thrombosis of the superﬁcial or 
deep venous sinuses of the brain. The ﬁrst ever reported case of the condition was back in 1825 and this was 
diagnosed at autopsy. It took more than 150 years before imaging modalities were developed that could diagnose 
cases earlier. With the advent of CT and MR venogram, the diagnosis has become much easier and is contributing to 
a larger number of cases being picked up. Despite that the incidence in Western literature stays low at 1.3-1.6 cases 
per 100,000 people. Middle Eastern and Asian countries seem to have a larger burden of CVT, possibly because of 
higher rates seen with infections and pregnancies.
CVT affects mostly young and middle aged adults and in this age group it tends to affect women much more than 
men. This is largely due to the cases seen during pregnancy and puerperium. Other transient or permanent factors 
predisposing to the condition are infections, use of oral contraception, acquired and inherited thrombophilia states, 
trauma and surgery.
Despite the presence of hemorrhagic strokes, the mainstay of treatment for these patients has always been 
anticoagulation. Often heparin, unfractionated or low molecular weight, is used followed by vitamin K antagonist, 
warfarin. A study conducted by Cundiff et al compared CVT patients who received heparin and warfarin to those who 
did not receive any treatment and found that this anticoagulation arm had a signiﬁcantly lower mortality. This 
however, came at the cost of a higher risk of major and intracranial bleeding and heparin induced thrombocytopenia. 
In addition, ﬂuctuations in INR and the requirement of frequent monitoring make this a cumbersome exercise for 
most patients.
Now with the advent of new direct oral anticoagulants (NOACs), there is a growing interest in expanding their use to 
other indications. These drugs have several advantages over vitamin K antagonists including rapid onset of action, 
predictable pharmacokinetic properties and few drug interactions. This precludes the need for frequent monitoring 
as is required for Warfarin. Several case reports and case series have been published over the past 5 years 
supporting the use of various NOACs in CVT patients and with good results. The three drugs reportedly used so far 
include Dabigatran (direct thrombin inhibitor), Apixaban and Rivaroxaban (factor Xa inhibitors). 
One series by Geisbuch et al, reported on seven patients who were treated with Rivaroxaban. These were 
compared with nine cases that received vitamin K antagonist. The authors reported no major differences in terms of 
outcomes, recanalization on MR Angiograms, and bleeding complications at a median of 8 month follow up. 
The largest series of NOAC use in CVT is by Mendonca et al. They reported on 15 cases of CVT treated with 
Dabigatran, four of which were switched from Warfarin because of adverse effects. 80% of the patients had 
recanalization and 87% had excellent outcomes at 19 months median follow up. Other case reports exist that report 
use of lower dose of Dabigatran (110mg twice daily) and shown similar good results.
Rao et al, recently published their case series of 3 CVT patients who were started on heparin and switched to 
Apixaban on discharge. All three patients had no therapy related complications and showed recanalization at follow 
up.
Despite this reported success, there are still uncertainties around the use of these agents for this particular 
indication. This niche will only be ﬁlled by well-designed randomized controlled trials with clear outcome deﬁnitions. 
The RESPECT CVT, TO-ACT, and EXCOA-CVT trials are currently underway and will hopefully provide robust 
evidence for use of NOACs in patients with cerebral venous thrombosis.
1
Rashid Hospital Dubai, UAE
2
Aga Khan Hospital, Karachi
Corresponding to: Mohammad Wasay MD, FRCP, FAAN, Aga Khan University, Karachi   Email: Mohammad.wasay@aku.edu
Date of submission: September 1, 2017   Date of revision: September 22, 2017   Date of acceptance: September 30, 2017
Conﬂict of interest: Author declares no conﬂict of interest.
Funding disclosure: Nil
Author's contribution:
Maria khan; concept, data collection, data analysis, manuscript writing, manuscript review
Mohammad Wasay; concept,data analysis, manuscript writing, manuscript review
Date of submission: September 1, 2017
Date of revision: September 22, 2017
Date of acceptance: September 30, 2017
0 4
1. Silvis SM, de Sousa DA, Ferro JM, Coutinho 
JM. Cerebral venous thrombosis. Nature 
Reviews Neurology. 2017 Sep;13(9):555.
2. Cundiff DK. Anticoagulants for cerebral 
venous thrombosis: harmful to patients?. 
Stroke. 2014 Jan 1;45(1):298-304.
3. Geisbüsch C, Richter D, Herweh C, Ringleb 
PA, Nagel S. Novel factor xa inhibitor for the 
treatment of cerebral venous and sinus 
thrombosis: ﬁrst experience in 7 patients. 
Stroke. 2014 Aug 1;45(8):2469-71.
P A K I S T A N  J O U R N A L O F N E U R O L O G I C A L S C I E N C E S V O L . 1 2 ( 4 )  -  2 0 1 7O C T D E C
REFERENCES:
4. Mendonça MD, Barbosa R, Cruz-e-Silva V, 
Calado S, Viana-Baptista M. Oral direct 
thrombin inhibitor as an alternative in the 
management of cerebral venous thrombosis: 
a series of 15 patients. International Journal of 
Stroke. 2015 Oct;10(7):1115-8.
5. Rao SK, Ibrahim M, Hanni CM, Suchdev K, 
Parker D, Rajamani K, Mohamed W. Apixaban 
for the treatment of cerebral venous 
thrombosis: A case series. Journal of the 
neurological sciences. 2017 Oct 15;381:318-
20.
